NDC 54868-2185-1 - Naftin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 54868-2185
- Requested NDC
- 54868-2185-1
- Package NDCs from labels
- 54868-2185-2, 54868-2185-1
- Manufacturer
- Physicians Total Care, Inc.
- Effective date
- 2013-03-04
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NAFTIN ® NAFTIFINE HCl 1% GEL | Physicians Total Care, Inc. | 2013-03-04 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54868-2185-2 | 2019-09-24 | C162847 | 48780-1 | 9350213a-4709-c013-e053-90daa90a1393 | NAFTIN ® NAFTIFINE HCl 1% GEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54868-2185-2 | Naftin | 1 in 1 CARTON | GEL | 1 | 2 | |
| 54868-2185-2 | Naftin | 40 g in 1 TUBE | GEL | 40 | 2 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54868-2185 | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | 2 package rows | 20130315_c8c13708-b35c-40bf-a911-12e4cffef2a7.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 54868-2185-1 | GM - Gram | 54868-2185 | f6b90bab-cbd4-425b-bf18-9fbfa3d215a7 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| NAFTIFINE HYDROCHLORIDE | ACTIVE INGREDIENT | 25UR9N9041 | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | |
| NAFTIFINE | ACTIVE MOIETY | 4FB1TON47A | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | |
| CARBOMER 934 | INACTIVE INGREDIENT | Z135WT9208 | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | |
| DIISOPROPANOLAMINE | INACTIVE INGREDIENT | 0W44HYL8T5 | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | NAFTIN (NAFTIFINE HYDROCHLORIDE) GEL [PHYSICIANS TOTAL CARE, INC.] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rohto Max Strength | NAPHAZOLINE HYDROCHLORIDE, POLYSORBATE 80 | The Mentholatum Company | e4b49550-1ca3-4bd7-854d-409b53fa5e26 | 2026-08-20 | Warnings | 6OZP39ZG8H |
| Droptics Dry Eye Relief | CARBOXYMETHYLCELLULOSE SODIUM,GLYCERIN,POLYSORBATE 80 | Droptics LLC | 29d7614b-f4b7-48e2-97c5-d1bff27731d2 | 2026-07-22 | Warnings | 6OZP39ZG8H |
| Rohto Cool Relief | NAPHAZOLINE HYDROCHLORIDE, POLYSORBATE 80 | The Mentholatum Company | dc8f1ff3-87ae-47ca-815f-5a0e34f8cf30 | 2026-06-19 | Warnings | 6OZP39ZG8H |
| Refresh Optive Mega-3 PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | 326cb5d6-c784-404f-9a13-6d69262dda6e | 2026-03-01 | Warnings | 6OZP39ZG8H |
| Naftifine Hydrochloride | NAFTIFINE HYDROCHLORIDE | Sun Pharmaceutical Industries, Inc. | 92d3ec30-2176-49cd-8a70-668ef65e7663 | 2026-02-12 | Warnings, Adverse reactions | 25UR9N9041 |
| Naftifine Hydrochloride | NAFTIFINE HYDROCHLORIDE | Sun Pharmaceutical Industries, Inc. | a740fc0d-45b3-411f-9dfd-f3d637b8a95f | 2025-11-14 | Warnings, Adverse reactions | 25UR9N9041 |
| Naftin | NAFTIFINE HYDROCHLORIDE | Sebela Pharmaceuticals Inc. | 6645994a-ecb3-277b-e053-2a91aa0a81e5 | 2025-11-08 | Warnings, Adverse reactions | 25UR9N9041 |
| Naftin | NAFTIFINE HYDROCHLORIDE | Legacy Pharma USA Inc. | 6c6ee055-4031-45a7-8561-ccd989343580 | 2025-07-30 | Warnings, Adverse reactions | 25UR9N9041 |
| Naftifine Hydrochloride | NAFTIFINE HYDROCHLORIDE | Sun Pharmaceutical Industries, Inc. | d50961c2-e97f-4583-91d6-7cafd25a8c3d | 2025-07-07 | Warnings, Adverse reactions | 25UR9N9041 |
| Refresh Digital PF | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | 97e83e68-6374-4df4-93f6-d707fc32748d | 2022-11-28 | Warnings | 6OZP39ZG8H |
| Refresh Digital | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | b2bd34d4-fab9-4f4b-9be2-5d30b55f5b81 | 2022-11-28 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | ebd0839e-2e1d-4e0e-986c-19f1f5c76358 | 2022-09-15 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, AND POLYSORBATE 80 | Allergan, Inc. | aaa943e4-7c38-4c5a-b7c0-5a656d8cafc0 | 2022-09-01 | Warnings | 6OZP39ZG8H |
| REFRESH Optive Mega-3 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | c5f2b3f2-2071-45bd-a010-67f848bc0233 | 2022-06-30 | Warnings | 6OZP39ZG8H |
| Miracle FootCream Lavender | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db520c80-2a2a-5eb1-e053-2995a90a5bb4 | 2022-03-28 | Warnings | 7FLD91C86K |
| Miracle FootCream Lemon | UREA, GLYCERIN, ALOE, DISODIUM EDTA | Aloe Vera Korea Co.,Ltd. | db525c63-29fd-2033-e053-2995a90a56b9 | 2022-03-28 | Warnings | 7FLD91C86K |
| f96d2943-9a0e-47b5-8c05-3d61ded6b051 | c8c13708-b35c-40bf-a911-12e4cffef2a7 | 2013-03-04 | Warnings, Adverse reactions | f96d2943-9a0e-47b5-8c05-3d61ded6b051 c8c13708-b35c-40bf-a911-12e4cffef2a7 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.